JNJ News

R40 coverage and dated third-party headlines for Johnson & Johnson (JNJ).

R40

R40 Coverage

News Aug 3, 2026

Johnson & Johnson's P/E Went 31 to 11 to 23 Without the Market Changing Its Mind. We Published a Chart Doing the Same Thing.

One outsized quarter distorts a trailing P/E twice — once when it arrives, and again four quarters later when it leaves. The second one is invisible, and our own Palo Alto coverage reasoned from it.

R40

External

February 2026

News Feb 3, 2026

Strong Buy on JNJ at $228.26

Insiders cashing out 22.8M shares; technical target $148.29, consensus $230.63.

@CapitalWisdomAI on X

External

January 2026

News Jan 30, 2026

Johnson & Johnson Guidance

Guides significant oncology sales growth, potentially doubling near-term; supports strong long-term growth.

@MultibaggAIHQ on X

News Jan 28, 2026

Biopharma Sentiment Snapped Higher

BPSI index jumped 78 to 90; aligns with price action and deal flow—continued M&A/IPOs expected.

@BowTiedBiotech on X

News Jan 27, 2026

Hospitals in Correction Mode

Stocks down 20-30%; focus on below 20x EV/EBITDA with 20%+ growth—structural tailwind intact.

@EquityInsightss on X